文献速递其他结缔组织病

抗拓扑异构酶I抗体与抗着丝点抗体在系统性硬化症中的预后价值——一项系统文献综述

The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature.
PubMed 文献 · Semin Arthritis Rheum · 2025-02-22

该系统综述检索了PubMed、Embase、Web of Science和Cochrane Library,纳入43项纵向系统性硬化症研究,评估抗拓扑异构酶I抗体(ATA)和抗着丝点抗体(ACA)对生存及疾病并发症的预后价值。结果显示支持ATA和ACA对死亡率具有独立预后价值的可靠证据很少;ATA与未来间质性肺病(ILD)发生相关,而ACA降低ILD发生风险。

要点

  • 21项研究中有1项发现ATA对死亡率具有预后价值,19项研究中有5项观察到ACA阳性患者生存率更高。
  • 7项研究中有4项显示ATA与未来ILD发生相关,4项研究中有3项显示ACA与ILD发生风险降低相关。
  • 其他疾病结局数据稀缺,支持ATA和ACA作为日常临床管理生物标志物的证据不足。

核心结论

  • 支持ATA和ACA对系统性硬化症死亡率具有独立预后价值的可靠证据很少。
  • ATA与未来ILD发生相关,而ACA降低ILD发生风险。
  • 为确定ATA和/或ACA作为日常临床管理和试验富集生物标志物的可能作用,需要在早期系统性硬化症中特征明确的队列开展未来研究。

研究设计与样本

  • 系统文献综述,检索PubMed(MEDLINE)、Embase、Web of Science和Cochrane Library,纳入报告ATA和ACA对生存或疾病并发症预后价值的纵向系统性硬化症研究。
  • 全文审查后排除关注事件<30例、ACA阳性和/或ATA阳性患者<30例以及根据QUIPS偏倚风险工具评为中高偏倚风险的研究。
  • 共检索到872篇文章,43项符合纳入标准。
  • 纳入研究的基线特征和研究设计异质性大:平均基线疾病病程从1年至12年不等,随访时间从1年至18.1年不等。

主要发现

  • 21项研究中有1项发现ATA对死亡率具有预后价值。
  • 19项可用研究中有5项观察到ACA阳性患者生存率更高。
  • 7项研究中有4项显示未来ILD发生与ATA相关。
  • 4项研究中有3项显示ACA与ILD发生风险降低相关。
  • 对于其他疾病结局,数据稀缺。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入研究在基线特征和研究设计方面异质性大:平均基线疾病病程从1年至12年不等,随访时间从1年至18.1年不等。
  • 对于其他疾病结局,数据稀缺。
  • 支持ATA和ACA对死亡率具有独立预后价值的可靠证据很少。
  • 为确定ATA和/或ACA作为日常临床管理和试验富集生物标志物的可能作用,需要在早期系统性硬化症中特征明确的队列开展未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-topoisomerase I antibodies (ATA) and anti-centromere antibodies (ACA) are the most prevalent systemic sclerosis (SSc) specific antibodies and are associated with distinct clinical phenotypes. This study reviews the prognostic potential of these autoantibodies for disease specific complications. METHODS: Literature searches of PubMed (MEDLINE), Embase, Web of Science and Cochrane Library were performed to identify longitudinal SSc-studies, reporting on the prognostic value of ATA and ACA for any aspect of survival or disease complications. After full text review, studies with <30 events of interest, <30 ACA positive and/or ATA positive patients, and with a moderate to high risk of bias (according to the QUIPS risk of bias tool) were excluded. RESULTS: Of 872 retrieved articles, 43 fulfilled the inclusion criteria. The included studies showed great heterogeneity in baseline characteristics and study design: mean baseline disease duration varied from 1 to 12 years and follow-up duration ranged from 1 to 18.1 years. One of the 21 studies found that ATA has prognostic value for mortality. Five of the nineteen available studies observed higher survival rates for ACA positive patients. Future development of ILD was associated with ATA in four of the seven studies, whereas ACA was associated with lower risk of ILD development in three out of four studies. For other disease outcomes, data are scarce. CONCLUSION: In conclusion, there is little sound evidence to support an independent prognostic value of ATA and ACA for mortality in SSc. ATA is associated with future ILD development, while ACA decreases the risk of ILD development. To determine the possible role of ATA and/or ACA as biomarkers for every day clinical management and trial enrichment, future studies are warranted in well described cohorts in early SSc.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Hoekstra EM, Liem SIE, Boonstra M, et al. The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature. Semin Arthritis Rheum. 2025. PMID: 40037059. doi:10.1016/j.semarthrit.2025.152667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。